Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fondaparinux versus FraxiParine in non-ST-segment elevation acute coronary syndrome in China
ChiCTR-TRC-09000446Phase 4Completed
- Sponsor
- Beijing An Zhen Hospital
- Start
- Jul 2009
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in non–ST-segment elevation acute coronary syndrome (NSTE-ACS), unstable angina and Non-ST-segment elevation myocardial infarction (NSTEMI) comparing FraxiParine group with fondaparinux group (2 arms). Primary endpoints: Incidence of major bleeding at 9 days and Incidence of death, myocardial infarction, or refractory ischemia. Started Jul 2009; status: completed.
02
Drugs
fondaparinuxnadroparin
03
Conditions
non–ST-segment elevation acute coronary syndrome (NSTE-ACS)unstable anginaNon-ST-segment elevation myocardial infarction (NSTEMI)
Beyond the preview
Go deeper on ChiCTR-TRC-09000446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-09000446.